

Please type a plus sign (+) inside the box → +

(Modified) PTO/SB/21 (6-98)
Approved for use through 09/30/2000. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

2002 S 0 330

OPIE

DEC 05 2002

PATENT & TRADEMA

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

7+

Application Number	10/004,201
Filing Date	November 1, 2001
First Named Inventor	Claus Bornaes, et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	0220us210

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<input type="checkbox"/> Transmittal Form; Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input checked="" type="checkbox"/> PTO-SB/08 (1449), 50 references	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Authorization to Charge Deposit Account Please charge Deposit Account No. 50-0990 for any additional fees associated with this paper or during the pendency of this application, including any extensions of time for consideration of the documents enclosed.		
Remarks		

RECEIVED

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Joanne R. Petithory, Reg. No. 42,995 Maxygen, Inc.	TECH CENTER 1600 2900
Signature		
Date	December 2, 2002	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date: December 2, 2002

Typed or printed name	Julie K. Mausen		
Signature		Date	December 2, 2002



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,
Washington, D.C. 20231

On December 2, 2002

By Julie K. Mausen
Julie K. Mausen

RECEIVED

U.S. PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 0220us210

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Claus Bornaes, et al.

Application No.: 10/004,201

Filed: November 1, 2001

For: New Multimeric Interferon Beta Polypeptides

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER
37 CFR § 1.97 and § 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-SB/08 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.


Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to a first Office action on the merits. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 50-0990. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Joanne R. Petithory
Reg. No. 42,995

Maxygen, Inc.
Patent Department
515 Galveston Drive
Redwood City, California 94063
Telephone: (650) 298-5300
Facsimile: (650) 298-5446
Customer No. 30560



Substitute for form 1449A PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known	
		Application Number	10/004,201
		Filing Date	November 01, 2001
		First Named Inventor	Claus Bornaes, et al.
		Group Art Unit	1644
		Examiner Name	Unassigned
		Attorney Docket Number	0220us210


U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, lines, Where Relevant Passages or Relevant Figures Appeal
		Number	Kind Code (if known)			
AA	4,588,585			Mark et al.	05/13/1986	
AB	4,686,191			Itoh et al.	08/11/1987	
AC	4,751,077			Bell et al.	06/14/1988	X
AD	4,769,233			Bell et al.	09/06/1988	
AE	4,904,584			Shaw	02/27/1990	
AF	4,914,033			Bell et al.	04/03/1990	
AG	4,917,888			Katre et al.	04/17/1990	
AH	4,966,843			McCormick et al.	10/30/1990	X
AI	5,218,092			Sasaki et al.	06/08/1993	
AJ	5,376,567			McCormick et al.	12/27/1994	
AK	5,382,657			Karasiewicz et al.	01/17/1995	
AL	5,545,723			Goetz et al.	08/13/1996	
AM	5,795,779			McCormick et al.	08/18/1998	
AN	5,908,626			Chang et al.	06/01/1999	

FOREIGN PATENT DOCUMENTS									
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	
		Office	Number	Kind Code (if known)					
AO	EP	0 083 069		A2	Kyowa Hakko Kogyo Co., Ltd.	07/06/1983			
AP	EP	0 041 313		A2	Biogen, Inc.	12/09/1981			
AQ	EP	0 260 350		A1	Cetus Corporation	03/23/1988			
AR	EP	0 287 075		B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988		X	
AS	EP	0 287 075 (English language translation of document AR)		B2	Dr. Rentschler Biotechnologie GmbH	10/19/1988			

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED



Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/004,201
		Filing Date	November 01, 2001
		First Named Inventor	Claus Bornaes, et al.
		Group Art Unit	1644
		Examiner Name	Unassigned
		Attorney Docket Number	0220us210

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
BJ	Derwent Abstract 012152872 for WO 98/48018, Cite No. AY	T
BK	Derwent Abstract 07723097 for JP 63267296, Cite No. BI	
BL	Fierlbeck et al., "Neutralising interferon β antibodies in melanoma patients treated with recombinant and natural interferon β " <i>Cancer Immunol Immunother</i> (1994) 39:263-268	
BM	KARPUSAS et al., "The Structure of Human Interferon- β at 2.2 A resolution" <i>Proc. Nat. Acad. Sci. USA</i> (1997) 94:11813-11818	
BN	KARPUSAS et al., "The Structure of Human Interferon- β : Implications for activity", <i>CMLS</i> 54 (1998) 1203-1216	
BO	MAYORGA et al., "Antibodies to Commercially Available Interferon-Beta Molecules in Multipule Sclerosis Patients Treated with Natural Interferon-Beta" <i>Int. Arch. Allergy Immunol</i> 1999; 118:368-371	
BP	MUNSCHAUER et al., "Managing Side Effects of Interferon-Beta in Patients with Relapsing-Remitting Multipule Sclerosis" <i>Clinical Therapeutics</i> vol. 19, No 5, 1997 883-893	
BQ	REDLICH et al., "Antibodies that neutralize human β interferon biologic activity recognizing a linear epitope: Analysis by synthetic peptide mapping" <i>Proc. Natl. Acad. Sci. USA</i> vol. 88, pp. 4040-4044 May 1991	
BR	RUDICK et al., "Incidence and significance of neutralizing antibodies to interferon beta-1a in multipule sclerosis" <i>Neurology</i> May 1989, 50: 1266-1272	
BS	RUNKEL et al., 1998, <i>Jour. Biol. Chem.</i> "Difference in activity between α and β Type I Interferons Explored by Mutational Analysis" 273, No. 14, pp. 8003-8008	
BT	RUNKEL et al., "Structural and Functional Differences Between Glycosylated and Non-Glycosylated Forms of Human Interferon- β (IFN- β)" <i>Pharmaceutical Research</i> vol. 15, No 4, 1998, 641-649	
BU	SENDA et al., "Refined Crystal Structure of Recombinant Murine Interferon- β at 2.15 A Resolution" <i>J. Mol. Biol.</i> (1995) 253, 187-207	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO <i>ATTENDEE TRADEMARKS</i> INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete if Known			
		Application Number	10/004,201		
		Filing Date	November 01, 2001		
		First Named Inventor	Claus Bornaes, et al.		
		Group Art Unit	1644		
		Examiner Name	Unassigned		
		Attorney Docket Number	0220us210		

RECEIVED

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office	Number	Kind Code (if known)				
	AT	EP	0 529 300	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		X
	AU	EP	0 529 300 (English language translation of document AT)	B1	Rentschler Biotechnologie GmbH & Co.	03/03/93		
	AV	EP	0 593 868	A1	Hoffmann-La Roche Inc.	04/27/1994		
	AW	WO	87/00056	A1	Cetus Corporation	01/15/1987		
	AX	WO	95/25170	A1	Biogen, Inc.	09/21/1995		
	AY	WO	98/48018	A1	Fraun-Hofer-Gesellschaft zur Forderung der Angewandten	10/29/1998	Derwent Abstract in English: item BJ	
	AZ	WO	99/02710	A1	Beth Israel Deaconess Medical Center	01/21/1999		
	BA	WO	99/03887	A1	Bolder Biotechnology, Inc.	01/28/1999		
	BB	WO	99/38891	A1	Beth Israel Deaconess Medical Center	08/05/1999		
	BC	WO	99/55377	A2	Applied Research Holdings	11/04/1999		
	BD	WO	99/67291	A2	Immunex Corporation	12/29/1999		
	BE	WO	00/23114	A3	Biogen, Inc.	04/27/2000		
	BF	WO	00/23472	A2	Biogen, Inc.	04/27/2000		
	BG	WO	00/26354	A1	Novo Nordisk A/S	05/11/2000		
	BH	WO	01/15736	A2	Maxygen ApS	03/08/2001		
	BI	JP	63267296		Toray Ind. Inc.	11/04/1988	Derwent Abstract in English: item BK	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A-B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/004,201
		Filing Date	November 01, 2001
		First Named Inventor	Claus Bornaes, et al.
		Group Art Unit	1644
		Examiner Name	Unassigned
		Attorney Docket Number	0220us210

RECEIVED
FEB 12 2002

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
	BV	STEWART et al., "Chemical Mutagenesis of Human Interferon-β: Construction, Expression in E. coli, and Biological Activity of Sodium Bisulfite-Induced Mutations" DNA, Vol 6 no 2 1987 p. 119-128	
	BW	TANIGUCHI et al, "The nucleotide sequence of human fibroblast interferon cDNA", Gene 10 (1980) 11-15	
	BX	YONG et al., "Interferon beta in the treatment of multiple sclerosis", Neurology 1998; 51: 682-689	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.